Sort   by:  
 Page size 
RAS genes are frequently mutated in cancer and have for decades eluded effective therapeutic attack. The National Cancer Institute’s RAS Initiative has a focus on understanding pathways and discovering therapies for RAS-driven cancers. Part of these efforts is the generation of novel reagents to ena...
ORGANISM(S): Homo Sapiens 
2019-09-03 | PXD012604 | panorama
Background: Conventional HER2-targeting therapies improve outcomes for patients with HER2-positive breast cancer (BC), defined as tumors showing HER2 protein overexpression by an immunohistochemistry (IHC) assay and/or ERBB2 gene amplification determined by in situ hybridization (ISH). Emerging HER2...
ORGANISM(S): Homo Sapiens 
2021-07-07 | PXD021893 | panorama
Immunotherapies are revolutionizing cancer care, producing durable responses and potentially cures in a subset of patients. However, response rates are low for most tumors, grade 3/4 toxicities are not uncommon, and our current understanding of tumor immunobiology is incomplete. While hundreds of im...
ORGANISM(S): Homo Sapiens 
2022-02-28 | PXD029167 | panorama
Sort   by:  
 Page size